politics

Southern Africa to Launch Mass Rollout of New HIV Preventive Drug

16 Haziran 2026France 24

Lenacapavir, a new HIV drug that requires administration only twice a year, offers over 99% protection against the virus. Following extensive research and clinical trials, it has received approval for mass rollout across Southern Africa.
This initiative targets countries severely affected by HIV/AIDS, including South Africa, Zambia, Eswatini, Zimbabwe, Lesotho, and Mozambique.
Southern Africa has been disproportionately affected by the HIV/AIDS epidemic, with millions living with the virus. The introduction of a highly effective preventive treatment like Lenacapavir could transform the landscape of HIV prevention in the region, shifting the focus from treatment to prevention.
The introduction of Lenacapavir marks a significant advancement in HIV prevention strategies, particularly in regions where the epidemic has had devastating effects. Its biannual administration could enhance adherence and accessibility, potentially leading to a substantial decrease in new infections.

NewsAI özeti

This article is for informational purposes only and does not constitute medical advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.